reference/26418524

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/26418524

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Comparative Study\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	84
issn	0161-6420
issueIdentifier	1
pageRange	72-84
publicationName	Ophthalmology
startingPage	72
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_34e753baa53a4c89e1b50d8988f267c1
bibliographicCitation	Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jan;127(1):72–84. doi: 10.1016/j.ophtha.2019.04.017. PMID: 30986442.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bcc3b26e834020fa3c098b4985eac238 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d73c1457574b24a2b8f2fbd5de480771 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_34ff065d0293542297b5bd4351acdf19 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b62b43cbfa7b2700932b11041d2e482 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2ebd8f3afbbf7306e2e1108faf3ae7a8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_089193880ac973cd70ea48a0008df40d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_699270a6bb0be769b002a84893c9d2fc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_682665f562bf58699c460ab519170178 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f9e4624b6d8145efabbaf90fff412778 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b3f3c09304caff8342919611c3d35c1
date	202001
identifier	https://pubmed.ncbi.nlm.nih.gov/30986442 https://doi.org/10.1016/j.ophtha.2019.04.017
isPartOf	https://portal.issn.org/resource/ISSN/0161-6420 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/6266
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
discusses	http://id.nlm.nih.gov/mesh/M000635524 http://id.nlm.nih.gov/mesh/M0441463 http://id.nlm.nih.gov/mesh/M0356369 http://id.nlm.nih.gov/mesh/M0018640 http://id.nlm.nih.gov/mesh/M0328153 http://id.nlm.nih.gov/mesh/M0185203 http://id.nlm.nih.gov/mesh/M0527034 http://id.nlm.nih.gov/mesh/M0556300
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D020256Q000188 http://id.nlm.nih.gov/mesh/D040262Q000627 http://id.nlm.nih.gov/mesh/D020533Q000627 http://id.nlm.nih.gov/mesh/D057135Q000188 http://id.nlm.nih.gov/mesh/D061067Q000627 http://id.nlm.nih.gov/mesh/D011993Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D014792Q000502 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D042461Q000037 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D020256Q000503 http://id.nlm.nih.gov/mesh/D020533Q000009 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D061067Q000009 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D011993Q000009 http://id.nlm.nih.gov/mesh/D057135Q000503 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D058449
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID638015 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10521 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8397 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_714b3f52d8149c3277181d9513b93112

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID252827371

Total number of triples: 63.